Editorial - Interpretation of Metaanalyses: Pitfalls Should Be More Widely Recognized

Abstract

On the basis of metaanalysis of randomized studies assessing the symptoms and radiological progression of patients with osteoarthritis (OA), investigators have concluded that health authorities and health insurers should not cover the costs of glucosamine and chondroitin, and new prescriptions to patients who have not received treatment should be discouraged. This conclusion has the potential to change current management of OA mainly in Europe, where these compounds are prescribed drugs. But should metaanalysis be considered the ultimate level of evidence and sole support for these conclusions? This editorial addresses this question.